Key regulatory milestones and financial updates position Sangamo Therapeutics Inc (SGMO) for potential growth despite funding ...

Sangamo Biosciences (SGMO) has disclosed a new risk, in the Manufacturing category. Sangamo Biosciences does not face any business risks ...

RBC Capital Mkts has recently reduced Sangamo Therapeutics Inc (SGMO) stock to Sector Perform rating, as announced on November 3, 2023, according to Finviz. Earlier, on April 28, 2023, BofA Securities ...

Wells Fargo raised the firm’s price target on Sangamo (SGMO) to $3 from $1 and keeps an Equal Weight rating on the shares. The firm views ...

RICHMOND, Calif., November 12, 2024 -- ( BUSINESS WIRE )--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported business highlights and third quarter 2024 financial ...

Now Gilead is spending a further $150 million upfront to access the cutting edge gene-editing technology of another Californian biotech, Sangamo. The ambition for this cancer-focused collaboration ...

Sangamo Therapeutics (SGMO) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of a loss of $0.03 per share. This compares to loss of $0.34 per share a year ago.

Sangamo Therapeutics SGMO is preparing to release its quarterly earnings on Tuesday, 2024-11-12. Here's a brief overview of what investors should keep in mind before the announcement. Analysts expect ...

Shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO – Get Free Report) reached a new 52-week high on Wednesday after HC Wainwright raised their price target on the stock from $5.00 to $10.00. HC ...

RICHMOND, Calif. (AP) — RICHMOND, Calif. (AP) — Sangamo Therapeutics Inc. (SGMO) on Tuesday reported third-quarter earnings of $10.7 million. On a per-share basis, the Richmond, California-based ...

On Tuesday, Sangamo Therapeutics Inc (SGMO) stock saw a modest uptick, ending the day at $2.16 which represents a slight increase of $0.42 or 24.14% from the prior close of $1.74. The stock opened at ...

Good afternoon and welcome to the Sangamo Therapeutics Third Quarter 2024 Teleconference Call. Please be advised that today's conference is being recorded. I would now like to turn the conference over ...